Clinical trials: Fulvestrant
- Drug or intervention Fulvestrant
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Postmenopausal Women
A Study of Single Dose of BL0175 in Postmenopausal Women
The goal of this clinical trial is to learn the safety and PK of the single dose of BL0175 Injection in postmenopausal women and to compare that with a single dose of Fulvestrant Injection.
- Trial name
- NCT07366632
- Testing
- BL0175, Fulvestrant
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Metastatic Breast Cancer
Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study
The goal of this clinical trial is to learn the comparative pharmacokinetic parameters between the test product and the Reference listed drug in healthy female volunteers The main question[s] it aims to answer are: To assess the…
- Trial name
- NCT06074757
- Testing
- Fulvestrant injection
- Where
- Jordan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Pharmacokinetics
Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration
Clinical study designed to assess the plasma pharmacokinetic profile and tolerability of Fulvestrant for Injectable Suspension after a single IM dose of Fulvestrant for Injectable Suspension compared to the reference product…
- Trial name
- NCT03324061
- Testing
- Fulvestrant for Injectable Suspension, Faslodex (Reference)
- Where
- 12 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Eagle Pharmaceuticals, Inc.
Healthy
Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
The purpose of this study is to demonstrate bioequivalence between the test drug product, fulvestrant Injection, 50 mg/mL, and the Reference Listed Drug, Faslodex® Injection, 50 mg/mL.
- Trial name
- NCT02795039
- Testing
- Fulvestrant
- Where
- 3 sites in Canada
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi
Healthy Postmenopausal Women
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
The goal of this clinical trial is to evaluate if KSHN001034 demonstrates safety, tolerability, and a comparable pharmacokinetic (PK) profile to the reference product, Faslodex® (fulvestrant), which is used for the treatment of…
- Trial name
- NCT06995482
- Testing
- KSHN001034, Fulvestrant
- Where
- 2 sites in United States, India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Breast Cancer
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with…
- Trial name
- NCT07207070
- Testing
- JS105, Dalpiciclib, Fulvestrant 50 Mg/mL Intramuscular Solution
- Where
- 2 sites in China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.